Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Jayamas Medica Industri Tbk's quarterly Other Current Receivables
increased
from Sep. 2025 (Rp4,707.43 Mil) to Dec. 2025 (Rp6,452.33 Mil) but then
stayed the same
from Dec. 2025 (Rp6,452.33 Mil) to Mar. 2026 (Rp5,542.48 Mil).
PT Jayamas Medica Industri Tbk's annual Other Current Receivables
declined
from Dec. 2023 (Rp4,040.40 Mil) to Dec. 2024 (Rp3,372.47 Mil) but then
increased
from Dec. 2024 (Rp3,372.47 Mil) to Dec. 2025 (Rp6,452.33 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk Other Current Receivables Chart
What does a Other Current Receivables of Rp5,542 Mil mean?
PT Jayamas Medica Industri Tbk (ISX:OMED) has a Other Current Receivables of Rp5,542 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on PT Jayamas Medica Industri Tbk and its competitors.
Is PT Jayamas Medica Industri Tbk's Other Current Receivables too high?
PT Jayamas Medica Industri Tbk's current Other Current Receivables is Rp5,542 Mil. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's Other Current Receivables compare to ISRG and BDX?
PT Jayamas Medica Industri Tbk's Other Current Receivables of Rp5,542 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on PT Jayamas Medica Industri Tbk and its competitors. PT Jayamas Medica Industri Tbk's current Other Current Receivables is Rp5,542 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Fairly Valued. The stock's GF Value™ is Rp239.19, compared to a current price of Rp218.00 — trading 8.9% below its estimated fair value. The current Other Current Receivables is Rp5,542 Mil. PT Jayamas Medica Industri Tbk's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current Other Current Receivables is Rp5,542 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be undervalued.
The current stock price of Rp218.00 is trading 8.9% below its estimated GF Value™ of Rp239.19.
GuruFocus considers PT Jayamas Medica Industri Tbk to be Fairly Valued.
Key valuation signals for ISX:OMED:
Other Current Receivables: Rp5,542 Mil
GF Value™: Rp239.19 vs. price of Rp218.00 (8.9% below fair value)
No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
90GF Score
Get the complete analysis for ISX:OMED
Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:OMED has been successfully added to your 
